Nephros Inc. NEPH
4.23
0.09
2.17%
as of 25 Sep
- Market cap
- $45.0M
- P/E
- 27.2×
Follow NEPH
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
22.91 | 45.29 | 46.12 | 36.38 |
+8 more quarters Free account |
P/S ratio |
1.87 | 1.66 | 2.76 | 2.80 | |
P/FCF ratio |
0.00 | 0.00 | 34.07 | 19.35 | |
P/Operating CF |
56.92 | (18.99) | 225.16 | 507.02 | |
P/B ratio |
3.24 | 2.97 | 5.08 | 5.02 | |
Price to Tangible BV |
3.60 | 3.35 | 5.78 | 5.74 | |
EV/Sales |
1.68 | 1.49 | 2.51 | 2.55 | |
EV/EBITDA |
19.76 | 35.49 | 36.71 | 28.86 | |
EV/Operating CF |
(52.71) | (81.90) | 28.67 | 16.85 | |
EV/FCF |
(44.33) | (60.26) | 31.03 | 17.66 | |
Quick Ratio |
2.63 | 2.98 | 2.82 | 3.17 | |
Current Ratio |
4.07 | 4.55 | 4.06 | 4.34 | |
Net Debt/EBITDA |
(3.78) | (32.40) | (108.00) | (14.86) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
1.48 | 1.50 | 1.51 | 1.52 | |
Operating CF/Net income |
0.57 | (11.94) | 3.71 | 0.29 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
6.08% | 6.64% | 8.35% | 7.09% | |
Selling, General and Administrative Expense of Revenue |
40.19% | 48.37% | 48.97% | 46.79% | |
Intangible Assets out of Total Assets |
0.08 | 0.09 | 0.09 | 0.10 | |
Share Based Compensation of Revenue |
1.01% | 1.15% | 1.67% | 1.47% | |
Graham Net Nets |
0.25 | 0.26 | 0.15 | 0.15 | |
Graham Number |
1.97 | 1.22 | 1.51 | 1.66 | |
Earnings Yield |
4.36% | 2.21% | 2.17% | 2.75% | |
Free Cash Flow Yield |
(2.03%) | (1.49%) | 2.94% | 5.17% | |
Revenue per Share |
0.55 | 0.49 | 0.45 | 0.45 | |
Operating CF per Share |
0.06 | (0.16) | 0.02 | 0.01 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.06 | (0.16) | 0.02 | 0.01 | |
Cash per Share |
0.43 | 0.38 | 0.51 | 0.49 | |
Shareholders Equity per Share |
1.10 | 1.00 | 0.96 | 0.94 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.10 | 1.00 | 0.96 | 0.94 | |
Free Cash Flow |
0.68 | (1.67) | 0.23 | 0.10 | |
Working Capital |
10.25 | 8.97 | 8.46 | 8.24 | |
Net Current Asset Value |
9.79 | 8.40 | 7.78 | 7.47 | |
EV/EBIT |
21.22 | 42.10 | 41.16 | 31.70 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
19.89% | 2.69% | 1.31% | 7.07% | |
Price to Operating Income |
23.61 | 46.88 | 45.19 | 34.74 | |
| Other line items | |||||
Average Receivables |
3.07 | 3.10 | 2.10 | 2.18 | |
Average Payables |
1.30 | 1.01 | 0.78 | 0.67 | |
Average Inventory |
3.39 | 2.79 | 2.92 | 2.92 | |
Average Assets |
14.01 | 12.79 | 12.43 | 11.82 | |
Average Common Equity |
10.78 | 10.00 | 9.39 | 9.09 |
Columns are period end dates